Do Kim
Stock Analyst at Piper Sandler
(2.02)
# 2,862
Out of 5,182 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $71.78 | -12.23% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $40.89 | +12.50% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $430.14 | -31.19% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $129.26 | -13.35% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $12.24 | +610.78% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.82 | +715.60% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $30.56 | -34.55% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $2.57 | +1,573.15% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $44.93 | -28.78% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $4.16 | +428.85% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $46.73 | -59.34% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.56 | +250.88% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $302.11 | -38.76% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.47 | +25,836.60% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $63.86 | -45.19% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.30 | +1,438.46% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $71.78
Upside: -12.23%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $40.89
Upside: +12.50%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $430.14
Upside: -31.19%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $129.26
Upside: -13.35%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $12.24
Upside: +610.78%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.82
Upside: +715.60%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $30.56
Upside: -34.55%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $2.57
Upside: +1,573.15%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $44.93
Upside: -28.78%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $4.16
Upside: +428.85%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $46.73
Upside: -59.34%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.56
Upside: +250.88%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $302.11
Upside: -38.76%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $3.47
Upside: +25,836.60%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $63.86
Upside: -45.19%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.30
Upside: +1,438.46%